Bayer, the parent company of Monsanto, was ordered to pay over $2 billion in a lawsuit alleging that its Roundup weedkiller causes cancer, in today's bite-sized hospital and health industry news from the District of Columbia, Georgia, and New Jersey.
- District of Columbia: Risant Health has added three new leaders to its organization. Deepak Sadagopan, who was previously COO of population health at Providence, has joined Risant as its business lead. Two physicians from Permanente Medical Group have also joined Risant as clinical leads. Chris Cable, chief clinical officer of KP Medical Foundation, will oversee clinical capabilities, including value-based care guides and AI-driven care tools, at Risant. Meanwhile, Marc Mora, executive medical director for Washington Permanente Medical Group, will oversee clinical network design and value-based strategies. "This new leadership structure ensures we have the infrastructure in place to continue to evolve the value-based platform, building on our existing momentum and successes," said Risant CEO Jaewon Ryu. "Deepak, along with Drs. Cable and Mora, will ensure we're developing business, clinical and technology solutions that enable health systems to accelerate their strategies and scale value-based care. Most importantly, this will help improve care and experience for patients, members, and clinicians." (Condon, Becker's Hospital Review, 3/19)
- Georgia: A meeting of CDC's Advisory Committee on Immunization Practices (ACIP), which was originally scheduled for Feb. 26 to Feb. 28, has now been rescheduled to April 15 to April 16. The meeting was unexpectedly delayed after Robert F. Kennedy Jr. became HHS secretary. According to an HHS spokesperson, the meeting was "postponed to accommodate public comment in advance of the meeting." During the meeting, ACIP members are expected to discuss the ongoing measles outbreak, as well as vaccines for COVID-19, human papillomavirus, mpox, respiratory syncytial virus, and other pathogens. (Alvarado, Healthcare Dive, 3/21)
- New Jersey: Bayer, the parent company of Monsanto, has been ordered to pay $2.065 billion in damages to a man who argued that the company's Roundup weedkiller was the cause of his cancer. In the case, the jury awarded $65 million in compensatory damages and $2 billion in punitive damages to the plaintiff. According to the Washington Post, Bayer has been dealing with Roundup litigation since it acquired Monsanto in 2018. Although Bayer has earned favorable verdicts in many of these trials, it has also paid around $10 billion to settle claims that Roundup and a chemical called glyphosate cause cancer. Bayer has also set aside an additional $5.9 billion for ongoing litigation. According to Bayer, it plans to appeal the verdict of the latest lawsuit to get it "overturned and the excessive and unconstitutional damage awards eliminated or reduced." (Frazin, The Hill, 3/24; Siegel, Washington Post, 3/22)
Don't miss out on the latest Advisory Board insights
Create your free account to access 1 resource, including the latest research and webinars.
Want access without creating an account?
You have 1 free members-only resource remaining this month.
1 free members-only resources remaining
1 free members-only resources remaining
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
You've reached your limit of free insights
Become a member to access all of Advisory Board's resources, events, and experts
Never miss out on the latest innovative health care content tailored to you.
Benefits include:
This content is available through your Curated Research partnership with Advisory Board. Click on ‘view this resource’ to read the full piece
Email ask@advisory.com to learn more
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
Benefits Include:
This is for members only. Learn more.
Click on ‘Become a Member’ to learn about the benefits of a Full-Access partnership with Advisory Board
Never miss out on the latest innovative health care content tailored to you.
